SCHEMBL10144151

SCHEMBL10144151

O=C(O)c1ccccc1Nc1ccc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.62
MAPT P10636 3/20 0.58
GFER P55789 1/20 0.58
NGLY1 Q96IV0 1/20 0.58
FTO Q9C0B1 1/20 0.58
MAPK9 P45984 1/20 0.58
MAPK10 P53779 1/20 0.58
TAS2R14 Q9NYV8 4/20 0.57
FABP3 P05413 1/20 0.57
FABP5 Q01469 1/20 0.57
PTGS1 P23219 2/20 0.56
AKR1C3 P42330 2/20 0.56
AKR1C2 P52895 2/20 0.56
TTR P02766 1/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 3/20 0.56
PTGS2 P35354 1/20 0.56
TEAD4 Q15561 1/20 0.56
CASP3 P42574 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1962364 0.88 POLB (0.53) FABP4MAPTGFERNGLY1FTO
Fenamic Acid SCHEMBL7265127 0.86 FABP4 (0.77) FABP4MAPTGFERNGLY1FTO
SCHEMBL7231990 0.85 FTO (0.64) FABP4MAPTGFERNGLY1FTO
SCHEMBL11572652 0.84 MAPT (0.49) FABP4MAPTGFERNGLY1FTO
SCHEMBL18109767 0.84 FABP4 (0.85) FABP4MAPTGFERNGLY1TAS2R14
SCHEMBL11652879 0.83 GRIK1 (0.62) FABP4MAPTGFERNGLY1FTO
SCHEMBL28133218 0.82 FABP4 (0.75) FABP4MAPTFTOTAS2R14FABP3
SCHEMBL7841736 0.80 FABP4 (0.85) FABP4MAPTGFERNGLY1TAS2R14
SCHEMBL16737179 0.80 MPO (0.62) MAPTGFERNGLY1TAS2R14AKR1C3
Fenamic Acid SCHEMBL29622832 0.80 FABP4 (0.92) FABP4MAPTGFERNGLY1TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX CORNING INCORPORATED 2012-01-26 US disclosed
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX CORNING INCORPORATED 2012-01-26 US disclosed
US-RE29585-E DYEING WOOL CIBA-GEIGY CORPORATION (US) 1978-03-21 US disclosed
US-4077953-A Tri-dentate metal complex azo pigments CIBA-GEIGY CORPORATION (US) 1978-03-07 US disclosed
US-3971738-A Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component CIBA-GEIGY AG (CH) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX GPR35, GPR65, GPR68 FABP4 501/4885MAPT 3699/4885GFER 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.